((R)-5-{4-[4-(4,4-Dimethyl-piperidin-1-yl)-benzoylsulfamoyl]-2-nitro-phenylamino}-6-phenylsulfanyl-hexyl)-carbamic acid tert-butyl ester | 406229-95-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ((R)-5-{4-[4-(4,4-Dimethyl-piperidin-1-yl)-benzoylsulfamoyl]-2-nitro-phenylamino}-6-phenylsulfanyl-hexyl)-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[(5R)-5-[4-[[4-(4,4-dimethylpiperidin-1-yl)benzoyl]sulfamoyl]-2-nitroanilino]-6-phenylsulfanylhexyl]carbamate
• CAS: 406229-95-6
• 化学式: C₃₇H₄₉N₅O₇S₂
• 分子量: 739.957
• InChiKey: RHTJELVXJSTRNO-MUUNZHRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  51
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  196
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  ((R)-5-{4-[4-(4,4-Dimethyl-piperidin-1-yl)-benzoylsulfamoyl]-2-nitro-phenylamino}-6-phenylsulfanyl-hexyl)-carbamic acid tert-butyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 4-((R)-5-Amino-1-phenylsulfanylmethyl-pentylamino)-N-[4-(4,4-dimethyl-piperidin-1-yl)-benzoyl]-3-nitro-benzenesulfonamide
  参考文献：
  名称：

  Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo

  摘要：

  Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X-L function, is described. Lead compounds generated by NMR screening and directed parallel synthesis displayed sub mu M binding but were strongly deactivated in the presence of serum. The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of inhibitors bound to both Bcl-X-L and HSA domain III indicated two potential optimization sites for separation of affinities. Modifications at both sites resulted in compounds with improved Bcl-X-L binding and greatly increased activity in the presence of human serum, culminating in 73R, which bound to Bcl-X-L with a K-i of 0.8 nM. In a cellular assay 73R reversed the protection afforded by Bcl-X-L overexpression against cytokine deprivation in FL5.12 cells with an EC50 of 0.47 mu M. 73R showed little effect on the viability of the human non small cell lung cancer cell line A549. However, consistent with the proposed mechanism, 73R potentiated the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft model.

  DOI：

  10.1021/jm050754u
• 作为产物：
  描述：

  4-氟-3-硝基苯磺酰胺 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 ((R)-5-{4-[4-(4,4-Dimethyl-piperidin-1-yl)-benzoylsulfamoyl]-2-nitro-phenylamino}-6-phenylsulfanyl-hexyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo

  摘要：

  Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X-L function, is described. Lead compounds generated by NMR screening and directed parallel synthesis displayed sub mu M binding but were strongly deactivated in the presence of serum. The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of inhibitors bound to both Bcl-X-L and HSA domain III indicated two potential optimization sites for separation of affinities. Modifications at both sites resulted in compounds with improved Bcl-X-L binding and greatly increased activity in the presence of human serum, culminating in 73R, which bound to Bcl-X-L with a K-i of 0.8 nM. In a cellular assay 73R reversed the protection afforded by Bcl-X-L overexpression against cytokine deprivation in FL5.12 cells with an EC50 of 0.47 mu M. 73R showed little effect on the viability of the human non small cell lung cancer cell line A549. However, consistent with the proposed mechanism, 73R potentiated the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft model.

  DOI：

  10.1021/jm050754u

文献信息

• Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo
  作者：Michael D. Wendt、Wang Shen、Aaron Kunzer、William J. McClellan、Milan Bruncko、Thorsten K. Oost、Hong Ding、Mary K. Joseph、Haichao Zhang、Paul M. Nimmer、Shi-Chung Ng、Alexander R. Shoemaker、Andrew M. Petros、Anatol Oleksijew、Kennan Marsh、Joy Bauch、Tilman Oltersdorf、Barbara A. Belli、Darlene Martineau、Stephen W. Fesik、Saul H. Rosenberg、Steven W. Elmore

  DOI：10.1021/jm050754u

  日期：2006.2.1

  Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X-L function, is described. Lead compounds generated by NMR screening and directed parallel synthesis displayed sub mu M binding but were strongly deactivated in the presence of serum. The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of inhibitors bound to both Bcl-X-L and HSA domain III indicated two potential optimization sites for separation of affinities. Modifications at both sites resulted in compounds with improved Bcl-X-L binding and greatly increased activity in the presence of human serum, culminating in 73R, which bound to Bcl-X-L with a K-i of 0.8 nM. In a cellular assay 73R reversed the protection afforded by Bcl-X-L overexpression against cytokine deprivation in FL5.12 cells with an EC50 of 0.47 mu M. 73R showed little effect on the viability of the human non small cell lung cancer cell line A549. However, consistent with the proposed mechanism, 73R potentiated the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft model.